Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-01-01 Epub Date: 2025-03-31 DOI:10.1080/14622416.2025.2478810

Huai Wu Yuan, Xia Huang, Min Ying Pan, Xuan Yu Chen, Yun Zhen Hu, Mei Hua Lin, Jian Er Wang, Yong Wu, Jun Hu, Mei Ling Cao, Hui Liang

{"title":"Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting.","authors":"Huai Wu Yuan, Xia Huang, Min Ying Pan, Xuan Yu Chen, Yun Zhen Hu, Mei Hua Lin, Jian Er Wang, Yong Wu, Jun Hu, Mei Ling Cao, Hui Liang","doi":"10.1080/14622416.2025.2478810","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to identify the impact of CYP2C19 polymorphism testing on clinical outcomes in patients who have undergone carotid artery stenting (CAS).Methods: This was a single-center retrospective cohort study. CYP2C19 polymorphisms were identified based on the presence of two normal functional alleles in normal metabolizers (NMs), a normal functional allele and a nonfunctional allele in intermediate metabolizers and two nonfunctional alleles in poor metabolizers. Patients were recommended for the CYP2C19 polymorphism testing followed by the change in dual antithrombotic drugs (DAPT) at the discretion of the supervising physician. The primary clinical endpoint was stent thrombosis (ST). Logistic regression was used to evaluate the relative risk of clinical outcomes.Results: A total of 273 patients were included. The relative risk of ST was not reduced in patients who underwent CYP2C19 polymorphism testing than in patients without this test (3.1% vs. 3.9%, OR = 0.914, 95% CI = 0.218-3.841). The ST in NMs and non-NMs was 3.4% and 2.9%, respectively, and showing no reduction in NMs (OR = 1.145, 95% CI = 0.162-8.105). Changing DAPT did not reduce the relative risk of ST compared with non-changing (2.3% vs. 3.2%, OR = 1.604, 95% CI = 0.024-107.033).Conclusions: CYP2C19 polymorphism was not related to stent thrombosis in patients with CAS.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"31-37"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988242/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2478810","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aimed to identify the impact of CYP2C19 polymorphism testing on clinical outcomes in patients who have undergone carotid artery stenting (CAS).

Methods: This was a single-center retrospective cohort study. CYP2C19 polymorphisms were identified based on the presence of two normal functional alleles in normal metabolizers (NMs), a normal functional allele and a nonfunctional allele in intermediate metabolizers and two nonfunctional alleles in poor metabolizers. Patients were recommended for the CYP2C19 polymorphism testing followed by the change in dual antithrombotic drugs (DAPT) at the discretion of the supervising physician. The primary clinical endpoint was stent thrombosis (ST). Logistic regression was used to evaluate the relative risk of clinical outcomes.

Results: A total of 273 patients were included. The relative risk of ST was not reduced in patients who underwent CYP2C19 polymorphism testing than in patients without this test (3.1% vs. 3.9%, OR = 0.914, 95% CI = 0.218-3.841). The ST in NMs and non-NMs was 3.4% and 2.9%, respectively, and showing no reduction in NMs (OR = 1.145, 95% CI = 0.162-8.105). Changing DAPT did not reduce the relative risk of ST compared with non-changing (2.3% vs. 3.2%, OR = 1.604, 95% CI = 0.024-107.033).

Conclusions: CYP2C19 polymorphism was not related to stent thrombosis in patients with CAS.

查看原文本刊更多论文

CYP2C19多态性检测对颈动脉支架植入术患者支架血栓形成风险的影响

目的：我们旨在确定CYP2C19多态性检测对颈动脉支架植入术（CAS）患者临床结果的影响。方法：这是一项单中心回顾性队列研究。CYP2C19多态性鉴定基于正常代谢者（NMs）中存在两个正常功能等位基因，中间代谢者中存在一个正常功能等位基因和一个非功能等位基因，差代谢者中存在两个非功能等位基因。建议患者进行CYP2C19多态性检测，然后根据指导医生的判断改变双抗血栓药物（DAPT）。主要临床终点为支架血栓形成（ST）。采用Logistic回归评估临床结果的相对风险。结果：共纳入273例患者。接受CYP2C19多态性检测的患者与未接受检测的患者相比，ST的相对风险没有降低（3.1%对3.9%,OR = 0.914, 95% CI = 0.218-3.841）。NMs组和非NMs组的ST分别为3.4%和2.9%，NMs组没有降低（OR = 1.145, 95% CI = 0.162 ~ 8.105）。与未改变DAPT相比，改变DAPT并没有降低ST的相对风险（2.3% vs. 3.2%, OR = 1.604, 95% CI = 0.024-107.033）。结论：CYP2C19多态性与CAS患者支架血栓形成无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.